Additional file 1 of The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials
Creators: name: Yu, Meixin
name: Wang, Ruxin
name: Pei, Ling
name: Zhang, Xiaofang
name: Wei, Jinjing
name: Wen, Yun
name: Liu, Han
name: Ye, Haowen
name: Wang, Jinghao
name: Wang, Lihong
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Molecular Biology
subject: Physiology
subject: FOS: Biological sciences
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Marine Biology
subject: Cancer
subject: Science Policy

description: Additional file 1: Figure S1. Risk of bias summary. Figure S2. Funnel plot and Egger’s test for the comparison of the incidence of overall Respiratory diseases with the use of GLP-1 receptor agonists versus placebo or other antidiabetic treatments. Figure S3. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Pulmonary edema. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S4. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Bronchitis. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S5. Forest plot of GLP-1 receptor agonists versus comparators on the risk of pneumonia. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S6. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Pulmonary fibrosis. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S7. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Dyspnoea. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S8. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Acute respiratory failure. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S9. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Pleural effusion. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S10. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Asthma. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S11. Forest plot of GLP-1 receptor agonists versus comparators on the risk of COPD. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S12. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Sleep apnoea syndrome. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S13. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Pulmonary embolism. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S14. Forest plot of GLP-1 receptor agonists versus comparators on the risk of Pulmonary hypertension. GLP-1RAs: GLP-1 receptor agonists, RR: risk ratios, CI: confidence Interval. Figure S15. Subgroup analyses (indication) of the effects of GLP-1 receptor agonists on the risk of overall respiratory disease. Figure S16. Subgroup analyses (control type) of the effects of GLP-1 receptor agonists on the risk of overall respiratory disease. Figure S17. Subgroup analyses (duration) of the effects of GLP-1 receptor agonists on the risk of overall respiratory disease. Figure S18. Forest plot of Albiglutide versus comparators on the risk of overall Respiratory diseases. GLP-1RAs, GLP-1 receptor agonists; RR, risk ratios; CI, confidence interval. Figure S19. Forest plot of Dulaglutide versus comparators on the risk of overall Respiratory diseases. GLP-1RAs, GLP-1 receptor agonists; RR, risk ratios; CI, confidence interval. Figure S20. Forest plot of Efpeglenatide versus comparators on the risk of overall Respiratory diseases. GLP-1RAs, GLP-1 receptor agonists; RR, risk ratios; CI, confidence interval. Figure S21. Forest plot of Exenatide versus comparators on the risk of overall Respiratory diseases. GLP-1RAs, GLP-1 receptor agonists; RR, risk ratios; CI, confidence interval. Figure S22. Forest plot of Liraglutide versus comparators on the risk of overall Respiratory diseases. GLP-1RAs, GLP-1 receptor agonists; RR, risk ratios; CI, confidence interval. Figure S23. Forest plot of Lixisenatide versus comparators on the risk of overall Respiratory diseases. GLP-1RAs, GLP-1 receptor agonists; RR, risk ratios; CI, confidence interval. Figure S24. Forest plot of Semaglutide versus comparators on the risk of overall Respiratory diseases. GLP-1RAs, GLP-1 receptor agonists; RR, risk ratios; CI, confidence interval.